PLAINSBORO, NJ, June 16, 2021 / PRNewswire / – Novo Nordisk announced that the American Diabetes Association (ADA )’s upcoming 81st Annual Scientific Sessions will unveil new data from more than 30 abstracts on the company’s approved drugs and investigational drugs that are widely used in diabetes and research Highlight obesity portfolio. The meeting takes place virtually 25-29 June 2021.
“The range of data we are proud to share in this scientific exchange reflects the huge unmet need that still exists and the need to better understand the links between obesity, diabetes and cardiovascular disease,” said Doug Langa, Senior Vice President, North America Operations and President of Novo Nordisk Inc. “We continue to leverage nearly 100 years of research and innovation to lead the cardiometabolic disease space and deliver relevant clinical data that supports better drugs and better treatment for patients.”
New data from our diabetes and obesity portfolio are presented, including results from the SUSTAIN FORTE phase 3 clinical trial evaluating a 2 mg test dose of Ozempic® (semaglutide) in adults with type 2 diabetes.
diabetes
Ozempic® (semaglutide) injection
- Efficacy and Safety of Semaglutide 2 vs. 1 mg Once Weekly in Type 2 Diabetes: Randomized SUSTAIN FORTE Study (Oral 101-OR)
- Efficacy and safety of semaglutide 2 vs. 1 mg once a week based on HbA1c and BMI baseline values: SUSTAIN FORTE subgroup analyzes (ePoster 665-P)
- Mobile health application as a real data resource – self-recorded weight reduction with semaglutide once a week (ePoster 645-P)
Rybelsus® (semaglutide) tablets
- Reaching an almost normal HbA1c with early onset of oral semaglutide: an exploratory subgroup analysis of PIONEER 1 (ePoster 663-P)
- Time to monitor blood glucose after starting oral semaglutide vs. empagliflozin treatment: an exploratory analysis of the PIONEER 2 study (ePoster 670-P)
Insulins
- Similar duration of hypoglycaemia with once-weekly insulin Icodec compared to once-daily insulin glargine U100 in insulin-naive or experienced patients with T2D (Oral 191-OR)
- CGM-based measurements for once-weekly insulin icodec versus once-daily insulin glargine U100 in insulin-treated patients with T2D: a post-hoc analysis (ePoster 731-P)
- CGM-derived parameters for once-weekly insulin Icodec vs once-daily insulin glargine U100 in insulin-naive patients with T2D (ePoster 732-P)
- Relationship between time in range and A1C in people with type 2 diabetes treated with basal insulin (ePoster 618-P)
- Relationship between the change in time in the range and A1C in people treated with basal insulin with type 2 diabetes (ePoster 618-P)
- Higher derived time in the area with IDegLira compared to insulin glargine U100 in patients with T2D (ePoster 606-P)
Cardiovascular care in type 2 diabetes
- Total cost of care in patients with T2D and cardiovascular disease: a comparative cohort study (OFFSET) (ePoster 82-LB)
- Cardiovascular autonomic neuropathy and risk of heart failure in participants with type 2 diabetes enrolled in the DEVOTE study (Oral 225-OR)
- Relationship between patient characteristics and cardiovascular diseases: a post-hoc analysis from the CAPTURE study (ePoster 974-P)
- Use of blood sugar lowering agents according to cardiovascular risk factors in people with T2D and with or without CVD in the CAPTURE study (ePoster 990-P)
obesity
In addition, the research on the use of Wegovy ™ (Semaglutide) injection 2.4 mg in adults with overweight or obesity and type 2 diabetes from the STEP program (Semaglutide Treatment Effect in People with Obesity) will be presented. Wegovy ™ was approved by the US Food and Drug Administration (FDA) on. authorized June 4th, 2021, to treat adults with obesity (BMI ≥ 30) or overweight (overweight) (BMI ≥ 27) who also have weight-related medical problems, to help them lose weight and maintain weight. Wegovy ™ should be used with a reduced calorie eating plan and increased physical activity. Selected highlights are:
- Semaglutide 2.4 mg once weekly Effects on glucose metabolism and prediabetes in overweight / obese adults in the STEP-1 study (Oral 81-OR)
- Treatment with semaglutide 2.4 mg once weekly Effects on cardiometabolic risk factors in adults with overweight / obesity and type 2 diabetes: STEP 2 post hoc analysis (Oral 80-OR)
The above summaries and presentations are representative of the data presented or published by Novo Nordisk. This press release contains forward-looking statements about investigational drugs currently under development by Novo Nordisk. As expected, drug development is at significant risk and there is no guarantee that future studies will reflect results similar to those presented at ADA. For more information on Novo Nordisk’s drug pipeline, please visit http://www.novoordisk.us.
About Ozempic®
Ozempic® (Semaglutide) Injection 0.5 mg or 1 mg is a once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist that is used with diet and exercise to improve blood sugar (glucose) in adults with type 2 diabetes mellitus and to reduce the risk of serious cardiovascular events such as heart attack, stroke, or death in adults with type 2 diabetes mellitus with known heart disease.
About Rybelsus®
Rybelsus® (semaglutide) tablets 7 mg or 14 mg is an analogue of the naturally occurring hormone GLP-1. Rybelsus® is a prescription medicine for adults with type 2 diabetes that, taken with diet and exercise, can improve blood sugar levels. Rybelsus® is the first and only GLP-1 receptor agonist in a pill. It is given once a day and is approved in two therapeutic doses: 7 mg and 14 mg.
About Wegovy ™
Wegovy ™ (Semaglutide) Injection 2.4 mg is an injectable prescription drug used with a reduced calorie eating plan and increased physical activity for adults with obesity (BMI ≥30) or overweight (overweight) (BMI ≥27) who are also weight-related Medicines struggle to help them lose weight and maintain them. Wegovy ™ was approved by the FDA on June 4, 2021. It is currently being reviewed in the European Union and other countries.
About Novo Nordisk
Novo Nordisk is a global healthcare company that has been making innovative medicines to help people with diabetes live longer, healthier lives for 95 years. This legacy has given us experience and skills that also enable us to help people fight other serious diseases such as obesity, hemophilia, and stunted growth. We remain firmly convinced that the formula for sustainable success is to stay focused, think long-term and act financially, socially and environmentally responsible. With US headquarters in New Jersey and manufacturing and research facilities in six states, Novo Nordisk employs nearly 6,000 people across the country. More information is available at www.novonordisk.us, Facebook, Instagram and Twitter.
Rybelsus® is a registered trademark of Novo Nordisk A / S.
Ozempic® is a registered trademark of Novo Nordisk A / S.
Wegovy ™ is a trademark of Novo Nordisk A / S.
Novo Nordisk is a registered trademark of Novo Nordisk A / S.
© 2021 Novo Nordisk All rights reserved. US21NNG00018 June 2021
SOURCE Novo Nordisk
